Seaport Therapeutics posts Phase 1 PK data for GlyphAgo bioavailability
Seaport Therapeutics reported Phase 1 PK results for GlyphAgo, citing a 6.8-fold bioavailability increase versus unmodified agomelatine and lower PK variability, with no food effect.